Aspen Bets Recovery on Filling Sterile Manufacturing Lines

Original Article by Raymond Steyn | Financial Mail | 17 September 2026

Aspen's turnaround hinges on filling its underused sterile manufacturing plants, as GLP-1 sales drive a share recovery.

Image | Rushay | Booysen | iStock/1335359769-1

Aspen’s turnaround hinges on filling its underused sterile manufacturing plants, as GLP-1 sales drive a share recovery.

Subscription Required

You must be a subscriber to access all of this content.

Already a subscriber? Log in here

Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.

Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.

GLP-1 medicines alone can’t solve SA’s diabetes crisis, experts warn, urging earlier screening, coordinated care and better food access.